EU External Trade - Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, put up in measured doses or in forms or packings for retail sale

Extra-EU sourcing of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, put up in measured doses or in forms or packings for retail sale is highly concentrated. 🇨🇭 Switzerland captures 54.5% of imports (€55.3B), followed by 🇺🇸 United States (25.8%). With an HHI of 3732, this Concentrated market exposes the EU to supply dependency risks.

European exports of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, put up in measured doses or in forms or packings for retail sale are concentrated on a few markets. 🇺🇸 United States accounts for 51.4% (€120.1B), ahead of 🇨🇭 Switzerland (9.5%). The top three destinations are 🇺🇸 United States, 🇨🇭 Switzerland, 🇬🇧 United Kingdom.

Within the EU, the leading importers of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, put up in measured doses or in forms or packings for retail sale are 🇧🇪 Belgium, 🇩🇪 Germany, 🇳🇱 Netherlands. 🇧🇪 Belgium accounts for 30.6% of EU imports.

In 2025, imports were rising (6.1%) and exports surging (16.9%) compared to the previous year.